Pfizer Likes Consumer Business Fit As Segment Grows 8%
This article was originally published in The Tan Sheet
Executive Summary
Increased sales of core brands including Advil, Caltrate and Robitussin drove up consumer sales 8% to $817 million for Pfizer’s fourth quarter. CEO Ian Read sees the segment “fitting nicely” in Pfizer following its animal health and nutrition business divestments.
You may also be interested in...
J&J Bit Off More Than McNeil Could Chew In 2006 Pfizer OTC Acquisition
McNeil scaled up its manufacturing “volume and complexity substantially” following J&J’s acquisition of Pfizer’s consumer business in 2006, says McNeil Consumer VP Shane Freedman. “Just a few years later, we had the recalls” that led eventually to a consent decree with FDA,” he says.
J&J Bit Off More Than McNeil Could Chew In 2006 Pfizer OTC Acquisition
McNeil scaled up its manufacturing “volume and complexity substantially” following J&J’s acquisition of Pfizer’s consumer business in 2006, says McNeil Consumer VP Shane Freedman. “Just a few years later, we had the recalls” that led eventually to a consent decree with FDA,” he says.
J&J Bit Off More Than McNeil Could Chew In 2006 Pfizer OTC Acquisition
McNeil scaled up its manufacturing “volume and complexity substantially” following J&J’s acquisition of Pfizer’s consumer business in 2006, says McNeil Consumer VP Shane Freedman. “Just a few years later, we had the recalls” that led eventually to a consent decree with FDA,” he says.